Oleg Selyutin

Statistics

Publications

Citations

460

H-Index

Active since

2011

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

WuXi AppTec (China)

United States Military Academy

Oleg Selyutin is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, drug discovery, and pharmacology.

Publications per year

2011–2020

Publications

I. Novel HCV NS5B polymerase inhibitors: Discovery of indole 2-carboxylic acids with C3-heterocycles

G. Anilkumar, Charles A. Lesburg, Oleg Selyutin et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 49 citations

Life Sciences, Medicinal Chemistry, Pharmacology +14

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms

Ling Tong, Wensheng Yu, Lei Chen et al. · Journal of Medicinal Chemistry · 2016 · 47 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Discovery of [<sup>11</sup>C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases

Ling Tong, Wenping Li, Michael Man‐Chu Lo et al. · Journal of Medicinal Chemistry · 2020 · 40 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Structure–Activity Relationship (SAR) Development and Discovery of Potent Indole-Based Inhibitors of the Hepatitis C Virus (HCV) NS5B Polymerase

Kevin X. Chen, Bancha Vibulbhan, Weiying Yang et al. · Journal of Medicinal Chemistry · 2011 · 30 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants

Wensheng Yu, Ling Tong, Bin Hu et al. · Journal of Medicinal Chemistry · 2016 · 28 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

1–5 of 21